Equity
BAUDREZ RX paid out €246,350 in dividends. That is 130% of the 2025 profit.
BAUDREZ RX paid out €246,350 in dividends. That is 130% of the 2025 profit.
The micro format states no turnover.
Debts rose by €231,024 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Short-term debts rose from €131,141 to €362,165.
Seven of the last ten came late. The 2024 accounts came in latest, 61 days after the end of the period.
Higher net result than 86% of companies in human health. Sector median €59,520 · 21,355 companies.
In July 2024, 17,816 companies had the same profile as BAUDREZ RX has now. Each dot stands for 45 companies, two years later.
The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,816 companies, not a prediction for BAUDREZ RX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
| Company | ||||
|---|---|---|---|---|
| BAUDREZ RX Assesse | €688,564 | €227,409 | 47.4% | - |
| JC GOEMINNE Namur | €756,737 | €210,445 | 74.7% | - |
| Dr. Jo DUCHATEAU Lier | €690,292 | €227,419 | 80.5% | - |
| DOCTEUR LEONIE DEUGOUE Remicourt | €712,732 | €216,255 | 44.2% | - |
| DERMALAUKES Etterbeek | €707,037 | €217,192 | 54.2% | - |
| Dr. De Clippel, gynaecologie-verloskunde Hoeilaart | €731,752 | €219,736 | 45.1% | - |
| DOCTEUR MATUS ONCOLOGY Trooz | €733,176 | €218,040 | 40.7% | - |
These companies have the same main activity as BAUDREZ RX: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €690,000 and €757,000, founded between 2006 and 2008.
BAUDREZ RX files the micro format. That format states no turnover. The gross margin rose from €109,548 in 2007 to €227,409 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.